文献速递胰腺与胆道疾病消化内镜

直肠双氯芬酸与吲哚美辛预防ERCP后胰腺炎(DIPPP):多中心、双盲、随机对照试验

Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial.
PubMed 文献 · Gut · 2025-06-06

在中国9家三级中心开展的多中心双盲随机对照试验,将1204例原生乳头、低危及高危PEP患者1:1分配至术前直肠100mg双氯芬酸组(n=600)或100mg吲哚美辛组(n=604)。双氯芬酸组PEP发生53例(8.8%),吲哚美辛组37例(6.1%)(RR 1.44;95%CI 0.96至2.16,p=0.074),差异未达统计学显著;试验因无效提前终止。结论:直肠双氯芬酸在预防PEP方面不优于等剂量吲哚美辛,支持现行指南。

要点

  • 双氯芬酸组PEP 8.8%(53/600)vs 吲哚美辛组6.1%(37/604),RR 1.44(95%CI 0.96-2.16,p=0.074),未达统计学显著。
  • 高危患者PEP:双氯芬酸组14.2%(35/247)vs 吲哚美辛组9.8%(26/266),p=0.124。
  • 低危患者PEP:双氯芬酸组5.1%(18/353)vs 吲哚美辛组3.3%(11/338),p=0.227。

核心结论

  • 术前直肠100mg双氯芬酸在预防PEP方面不优于等剂量直肠吲哚美辛。
  • 研究结果支持现行临床实践指南中对于无禁忌证患者使用100mg吲哚美辛或双氯芬酸预防PEP的推荐。

研究设计与样本

  • 多中心、双盲、随机对照试验,在中国9家三级中心开展。
  • 纳入原生乳头、PEP低危及高危患者,1:1随机分配至直肠100mg双氯芬酸组(n=600)或直肠100mg吲哚美辛组(n=604),于ERCP前给药。
  • 主要结局为按Cotton共识定义的PEP发生,采用意向性治疗原则分析。
  • 预定第一次期中分析后因无效提前终止;2023年6月至2024年5月 randomization 1204例。

主要发现

  • 主要结局PEP:双氯芬酸组53/600(8.8%)vs 吲哚美辛组37/604(6.1%),相对危险度1.44(95%CI 0.96至2.16,p=0.074)。
  • 高危患者PEP:双氯芬酸组35/247(14.2%)vs 吲哚美辛组26/266(9.8%),p=0.124。
  • 低危患者PEP:双氯芬酸组18/353(5.1%)vs 吲哚美辛组11/338(3.3%),p=0.227。
  • 两组其他ERCP相关并发症无差异。

关键数值与推荐

  • PEP定义采用Cotton共识。
  • PEP预防用药:直肠100mg双氯芬酸或100mg吲哚美辛,ERCP前给药。
  • 主要结局相对危险度1.44(95%CI 0.96至2.16,p=0.074),未达统计学显著。

临床怎么用

  • 研究结果支持现行临床实践指南中对于无禁忌证患者使用100mg吲哚美辛或双氯芬酸预防PEP的推荐。

局限性

  • 试验因无效提前终止于预定第一次期中分析后。
  • 主要结局相对危险度95%CI较宽(0.96至2.16)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent meta-analyses suggested diclofenac may be superior to indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). The aim of our study was to compare the efficacy of 100 mg rectal indomethacin versus diclofenac on PEP incidences. DESIGN: This multicentre, double-blinded, randomised controlled trial was conducted in nine tertiary centres in China. Patients with low and high risk for PEP and native papilla were randomly allocated (1:1) to receive 100 mg diclofenac or 100 mg indomethacin rectally before ERCP. The primary outcome was the occurrence of PEP defined by the Cotton consensus. The intention-to-treat principle was conducted for the analysis. RESULTS: The trial was terminated early for futility after the predetermined first interim analysis. Between June 2023 and May 2024, 1204 patients were randomised into the diclofenac group (n=600) or indomethacin group (n=604). Baseline characteristics were balanced. The primary outcome occurred in 53 patients (8.8%) of 600 patients allocated to the diclofenac group and 37 patients (6.1%) of 604 patients allocated to the indomethacin group (relative risk 1.44; 95% CI 0.96 to 2.16, p=0.074). PEP occurred in 35 (14.2%) of 247 high-risk patients in the diclofenac group and 26 (9.8%) of 266 high-risk patients in the indomethacin group (p=0.124). PEP incidences were also comparable in low-risk patients between the two groups (18/353 (5.1%) vs 11/338 (3.3%), p=0.227). Other ERCP-related complications did not differ between the two groups. CONCLUSION: Pre-procedure 100 mg rectal diclofenac was not superior to the same dose of rectal indomethacin regarding preventing PEP. These findings supported current clinical practice guidelines of 100 mg indomethacin or diclofenac for PEP prophylaxis in patients without contraindications. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT05947461).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kang X, Xia M, Wang J, et al. Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial. Gut. 2025. PMID: 40113243. doi:10.1136/gutjnl-2024-334466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。